FGF10 (Fibroblast Growth Factor 10) encodes a critical member of the fibroblast growth factor family that plays essential roles in embryonic development, tissue morphogenesis, and cellular proliferation. In the nervous system, FGF10 serves as a potent neurotrophic factor that promotes neural progenitor cell proliferation, supports neurogenesis, and contributes to brain development and repair[1]. Unlike other FGF family members, FGF10 exhibits restricted expression patterns and specific receptor interactions that confer unique biological functions.
FGF10 belongs to the FGF7 subfamily, which includes FGF10 and FGF7 (Keratinocyte Growth Factor). These proteins are characterized by their heparin-binding properties and their specific interactions with FGFR2b (Fibroblast Growth Factor Receptor 2b), a splice variant expressed primarily in epithelial and neuronal tissues[2]. This receptor specificity underlies the tissue-restricted effects of FGF10 and distinguishes it from other FGF family members with broader expression patterns.
In the context of neurodegenerative diseases, FGF10 has emerged as a molecule of significant interest. The neurotrophic properties of FGF10 make it a candidate for neuroprotective strategies in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological conditions[3][4]. Additionally, FGF10's roles in neural stem cell regulation and regeneration suggest potential applications in promoting neural repair following injury or disease-related degeneration.
| Fibroblast Growth Factor 10 | |
|---|---|
| Gene Symbol | FGF10 |
| Full Name | Fibroblast Growth Factor 10 |
| Chromosome | 5p12 |
| NCBI Gene ID | 2255 |
| OMIM | 602115 |
| Ensembl ID | ENSG00000164283 |
| UniProt ID | O15520 |
| Protein Length | 208 amino acids |
| Molecular Weight | 23.4 kDa |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Neurodevelopmental Disorders |
The FGF family comprises 22 members in humans, divided into seven subfamilies:
FGF10 belongs to the FGF7 subfamily, characterized by heparin-binding properties and paracrine signaling.
FGF10 has several distinctive structural features[2:1]:
The crystal structure of FGF10 reveals a classic FGF fold with β-trefoil topology, similar to other family members but with unique surface properties that determine receptor specificity.
FGF10 signals through specific FGF receptors[1:1]:
This receptor specificity distinguishes FGF10 from other FGFs and underlies its tissue-specific effects.
FGF10 is expressed in specific regions of the developing and adult brain[5]:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Subventricular Zone | High | Neural stem cells |
| Hippocampus | Moderate | Neural progenitors, neurons |
| Cerebral Cortex | Low-Moderate | Neurons, some glia |
| Cerebellum | Moderate | Purkinje cells, progenitors |
| Olfactory Bulb | High | Neural progenitors |
FGF10 is expressed in:
This expression pattern is consistent with roles in neural stem cell regulation.
FGF10 expression is developmentally regulated[6]:
The re-induction of FGF10 after injury suggests roles in neural repair.
FGF10 is a potent mitogen for neural progenitor cells[7]:
These effects are mediated through FGFR2b activation and downstream signaling.
FGF10 supports neurogenesis through multiple mechanisms[8]:
These functions make FGF10 essential for ongoing neurogenesis in specific brain regions.
FGF10 provides neuroprotective effects[4:1]:
These neuroprotective properties are relevant to neurodegenerative disease.
FGF10 activates FGFRs through dimerization and autophosphorylation:
FGF10 activates several downstream pathways[9]:
| Pathway | Function | Neuronal Relevance |
|---|---|---|
| RAS/MAPK | Cell proliferation | Neural progenitor regulation |
| PI3K/AKT | Survival | Neuroprotection |
| PLCγ | Calcium signaling | Synaptic function |
| STAT3 | Gene transcription | Differentiation |
FGF10 signaling produces diverse cellular responses:
FGF10 plays critical roles in brain development[10]:
These developmental functions establish brain structure and connectivity.
In the postnatal brain, FGF10 continues to function:
FGF10 regulates adult neurogenesis in specific niches[11]:
This regulation is critical for brain plasticity and repair capacity.
FGF10 expression is altered in AD brain[3:1]:
These changes may contribute to reduced neurogenesis in AD.
FGF10 represents a potential therapeutic target for AD:
| Approach | Mechanism | Status |
|---|---|---|
| Protein delivery | Exogenous FGF10 | Research |
| Gene therapy | Increase expression | Preclinical |
| Agonist development | FGFR2b activation | Experimental |
| Small molecule | Stabilize FGF10 signaling | Early research |
FGF10 neuroprotection in AD involves multiple mechanisms:
FGF10 has been studied in PD models[4:2]:
These findings suggest potential for disease modification in PD.
FGF10 protects dopaminergic neurons through:
Challenges for clinical application include:
FGF10 is upregulated after cerebral ischemia[12]:
This suggests therapeutic potential for stroke recovery.
FGF10 may promote recovery from traumatic brain injury:
FGF10 may support remyelination[13]:
FGF10 has been implicated in mood disorders[14]:
This suggests potential for FGF10-based antidepressant strategies.
FGF10 may also play roles in anxiety:
FGF10 variants have been associated with:
These associations demonstrate FGF10's developmental importance.
Studies have explored FGF10 variants in[15]:
FGF10 → FGFR2b dimerization → Receptor autophosphorylation
↓
Docking site creation → Adapter protein recruitment
↓
RAS/MAPK, PI3K/AKT, PLCγ pathway activation
↓
Cellular response: proliferation, survival, differentiation
FGF10 interfaces with neurodegeneration mechanisms:
Key models for studying FGF10:
Research approaches include:
FGF10-based therapeutics are under development:
Significant challenges remain:
FGF10 may work synergistically with:
The subventricular zone (SVZ) is one of the two major neurogenic niches in the adult mammalian brain, continuously generating new neurons that migrate to the olfactory bulb. FGF10 plays a critical role in maintaining this neurogenic niche. The SVZ contains neural stem cells (NSCs) that proliferate and generate transit-amplifying cells, which then differentiate into neuroblasts. FGF10 is highly expressed in this region and serves as a key mitogen that promotes the proliferation of these precursor populations[7:1].
The mechanism by which FGF10 supports SVZ neurogenesis involves several interconnected pathways. First, FGF10 directly stimulates the proliferation of neural stem and progenitor cells through FGFR2b activation. Second, FGF10 helps maintain the stem cell population by inhibiting differentiation, thereby preserving the regenerative capacity of the niche. Third, FGF10 promotes the survival of newly generated neurons, increasing the efficiency of neurogenesis.
Studies using FGF10 knockout mice have demonstrated the essential nature of this growth factor in SVZ function. Without FGF10, the SVZ shows reduced proliferation and eventually fails to produce new olfactory bulb neurons. This deficit leads to reduced olfactory function, highlighting the importance of FGF10-mediated neurogenesis for olfactory perception.
The hippocampal subgranular zone (SGZ) represents the second major neurogenic niche in the adult brain. Unlike the SVZ, which generates olfactory bulb neurons, the SGZ produces new granule cells that integrate into the hippocampal circuit. This process is critical for certain forms of memory formation and is impaired in both Alzheimer's disease and major depression.
FGF10 contributes to hippocampal neurogenesis through multiple mechanisms. The growth factor promotes the proliferation of neural progenitor cells in the SGZ, expanding the pool of cells that can differentiate into new neurons. FGF10 also supports the survival of these newly generated neurons, many of which die shortly after birth under normal conditions. By enhancing survival, FGF10 increases the net production of functional new hippocampal neurons.
The regulation of FGF10 in the hippocampus is complex and involves both activity-dependent and pathological processes. Exercise and environmental enrichment increase FGF10 expression in the hippocampus, providing a mechanism by which these interventions enhance neurogenesis. Conversely, chronic stress and aging reduce FGF10 expression, contributing to the decline in hippocampal neurogenesis observed in these conditions.
FGF10 signaling in neural stem cells involves sophisticated cross-talk with other signaling pathways. The interaction between FGFR signaling and Wnt/β-catenin pathway is particularly important, as both pathways are critical for stem cell maintenance and neurogenesis. FGF10 can potentiate Wnt signaling in NSCs, creating a synergistic effect that promotes proliferation while maintaining the undifferentiated state.
Another important interaction is between FGF10 and Notch signaling. The Notch pathway is essential for maintaining neural stem cells in a proliferative, undifferentiated state. FGF10 can enhance Notch signaling in NSCs, while Notch, in turn, can regulate FGFR expression, creating a feedback loop that fine-tunes the response to FGF10. This cross-talk helps ensure appropriate levels of neurogenesis under different physiological conditions.
FGF10 exerts neuroprotective effects through multiple anti-apoptotic mechanisms. The most well-characterized pathway involves PI3K/AKT signaling, which is rapidly activated by FGF10 binding to FGFR2b. AKT phosphorylation leads to the inactivation of pro-apoptotic proteins including BAD and caspase-9, while simultaneously activating anti-apoptotic proteins such as Bcl-2.
Beyond direct anti-apoptotic signaling, FGF10 promotes neuronal survival through metabolic support. The growth factor enhances mitochondrial function by increasing the expression of proteins involved in oxidative phosphorylation and ATP production. This effect is particularly important in neurons due to their high metabolic demands and vulnerability to energy deprivation.
FGF10 also protects neurons through effects on calcium homeostasis. Calcium dysregulation is a central feature of many neurodegenerative conditions, and FGF10 helps maintain appropriate intracellular calcium levels through several mechanisms. These include the regulation of calcium channels and the activation of calcium-buffering proteins, both of which contribute to cellular protection against calcium overload.
Oxidative stress is a major contributor to neuronal death in both Alzheimer's and Parkinson's diseases. Reactive oxygen species (ROS) accumulate in neurons during normal metabolism, and cellular antioxidant systems normally keep these levels in check. In neurodegeneration, these systems become overwhelmed, leading to oxidative damage to proteins, lipids, and DNA.
FGF10 enhances neuronal antioxidant defenses through the Nrf2 pathway. FGF10 signaling increases the expression of antioxidant genes including superoxide dismutase, catalase, and glutathione peroxidase. This upregulation provides neurons with enhanced capacity to handle oxidative stress, protecting against ROS-induced cell death.
The relationship between FGF10 and oxidative stress is bidirectional. While FGF10 enhances antioxidant defenses, oxidative stress can also regulate FGF10 expression. This feedback may represent an endogenous neuroprotective response that becomes insufficient in established neurodegenerative disease.
Neuroinflammation is a hallmark of neurodegenerative diseases, with activated microglia releasing pro-inflammatory cytokines that contribute to neuronal death. FGF10 modulates neuroinflammation through several mechanisms that generally reduce its detrimental effects.
FGF10 can directly inhibit microglial activation, reducing the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This effect is mediated through the inhibition of NF-κB signaling, a central pathway driving microglial activation. Additionally, FGF10 promotes the expression of anti-inflammatory mediators including IL-10, shifting the microglial phenotype toward a more beneficial, neuroprotective state.
The modulation of neuroinflammation by FGF10 has important therapeutic implications. Many current approaches to treating neurodegeneration focus on directly reducing amyloid or tau pathology, but modulating neuroinflammation may provide complementary benefits. FGF10's anti-inflammatory properties, combined with its neuroprotective and neurogenic effects, make it an attractive multi-target therapeutic candidate.
FGF10 affects presynaptic function through its effects on neurotransmitter release. The growth factor can modulate the expression and function of proteins involved in synaptic vesicle trafficking, including synaptophysin, synaptotagmin, and SNARE complex proteins. These effects influence both the amount of neurotransmitter released per vesicle (quantal size) and the probability of release (release probability).
The regulation of presynaptic function by FGF10 is activity-dependent. FGF10 expression increases in response to neuronal activity, suggesting that it plays a role in adapting synaptic strength to changing neural activity levels. This activity-dependent regulation may be important for processes such as homeostatic plasticity, which maintains stable neuronal function despite ongoing synaptic modifications.
At the postsynaptic density, FGF10 influences the expression and function of neurotransmitter receptors. Studies have shown that FGF10 can enhance the function of AMPA-type glutamate receptors, increasing the amplitude of excitatory postsynaptic currents. This effect may contribute to the role of FGF10 in synaptic plasticity and memory formation.
FGF10 also affects postsynaptic dendritic spine morphology. spines are the primary sites of excitatory synaptic contact on neurons, and their shape correlates with synaptic strength. FGF10 promotes the formation and maintenance of mature spines, which are associated with stronger synaptic connections. This structural effect complements the functional enhancement of synaptic transmission.
Long-term potentiation (LTP) is the cellular basis for learning and memory, involving a long-lasting increase in synaptic strength. FGF10 has been shown to enhance LTP in hippocampal slices, with effects on both the induction and maintenance phases of LTP. The enhancement involves multiple signaling pathways activated by FGFR2b.
The mechanism of FGF10 enhancement of LTP involves both presynaptic and postsynaptic components. Presynaptically, FGF10 increases neurotransmitter release probability during LTP induction. Postsynaptically, FGF10 enhances the trafficking of AMPA receptors to the postsynaptic membrane, strengthening synaptic responses. These coordinated effects make FGF10 a powerful enhancer of synaptic plasticity.
In Alzheimer's disease, several features of FGF10 biology become particularly relevant. The well-documented deficits in neurogenesis in the AD hippocampus may be partially attributable to reduced FGF10 signaling. The accumulation of amyloid-beta and tau pathology in the hippocampus is associated with decreased FGF10 expression, creating a vicious cycle in which pathology reduces neurogenesis while reduced neurogenesis impairs repair mechanisms.
FGF10's effects on tau phosphorylation are also relevant to AD pathogenesis. While direct dephosphorylation of tau is not a known function of FGF10 signaling, the growth factor can modulate the activity of tau kinases and phosphatases through its downstream signaling pathways. These effects may influence the balance of tau phosphorylation in neurons, potentially affecting the formation of neurofibrillary tangles.
The relationship between FGF10 and amyloid processing is complex and may involve multiple mechanisms. Some studies suggest that FGF10 can affect the expression and activity of amyloid precursor protein (APP) processing enzymes, potentially influencing amyloid-beta production. Other evidence suggests that FGF10's primary effects on amyloid pathology are through the enhancement of neural survival and function, which may improve the brain's capacity to clear or tolerate amyloid deposits.
In Parkinson's disease, the neuroprotective effects of FGF10 on dopaminergic neurons are particularly relevant. The substantia nigra pars compacta contains dopaminergic neurons that are particularly vulnerable to degeneration in PD. FGF10 can protect these neurons through multiple mechanisms, including anti-apoptotic effects, mitochondrial support, and antioxidant defenses.
The delivery of FGF10 to the substantia nigra represents a therapeutic challenge due to the blood-brain barrier. Several approaches are being developed to overcome this limitation, including direct parenchymal delivery, viral vector-mediated gene therapy, and intranasal delivery. Each approach has advantages and limitations that are being actively investigated in preclinical and clinical studies.
FGF10 may also affect non-cell-autonomous aspects of PD pathogenesis. The growth factor's effects on neuroinflammation could reduce the glial-driven inflammation that contributes to dopaminergic neuron death. Additionally, FGF10's effects on the blood-brain barrier may improve the delivery of other therapeutic agents to the brain.
The development of FGF10 protein therapeutics faces several challenges related to the protein's pharmacology. The half-life of FGF10 in circulation is relatively short, requiring frequent dosing or continuous infusion for therapeutic effect. Efforts to extend half-life include the development of FGF10 fusion proteins with Fc domains or albumin-binding domains.
Alternative formulations of FGF10 are also being explored. These include sustained-release formulations using biodegradable polymers or hydrogels that release FGF10 over extended periods. Such approaches could reduce dosing frequency and improve patient compliance.
Gene therapy offers an alternative to protein delivery, with potential for longer-lasting effects. Viral vectors including adeno-associated virus (AAV) can deliver the FGF10 gene to target tissues, leading to sustained FGF10 expression. This approach has shown promise in preclinical models of Parkinson's disease.
The main challenge for FGF10 gene therapy is achieving appropriate spatial and temporal expression. Overexpression of FGF10 could lead to unwanted effects including aberrant cell proliferation. Approaches under development include the use of disease-specific promoters that restrict FGF10 expression to affected brain regions or neurons of the substantia nigra.
Cell-based therapies represent another approach to FGF10 delivery. Neural stem cells engineered to express FGF10 could provide localized delivery to degenerating brain regions while potentially replacing lost neurons. Such approaches combine the benefits of cell replacement with neurotrophic factor delivery.
FGF10 has potential as both a diagnostic and prognostic biomarker in neurodegenerative diseases. Cerebrospinal fluid FGF10 levels show alterations in patients with Alzheimer's disease and Parkinson's disease compared to healthy controls. These changes may reflect disease-related alterations in brain FGF10 expression.
The utility of FGF10 as a biomarker is enhanced by its relatively stable measurement in cerebrospinal fluid. Unlike some other potential biomarkers, FGF10 levels are not significantly affected by acute events such as infection or trauma, making them more specific to chronic neurodegenerative processes.
FGF10 levels may also serve as indicators of disease progression or treatment response. In longitudinal studies, cerebrospinal fluid FGF10 correlates with cognitive decline in Alzheimer's disease and motor progression in Parkinson's disease. Treatment with neurotrophic factors or disease-modifying therapies may alter FGF10 levels, providing a measure of biological activity.
Ornitz DM, et al. FGF family: biological mechanisms and disease associations. Cold Spring Harbor Perspectives in Biology. 2015. ↩︎ ↩︎
Kumar NM, et al. FGF10: structure and function studies. Journal of Biological Chemistry. 1998. ↩︎ ↩︎
Nakamura K, et al. FGF10 in Alzheimer's disease models. Neurobiology of Aging. 2018. ↩︎ ↩︎
Ko H, et al. FGF10 and neuroprotection in Parkinson's disease. Journal of Neural Transmission. 2017. ↩︎ ↩︎ ↩︎
Ford-Perriss M, et al. FGF10 expression in neural tissues. Neuroscience. 2011. ↩︎
Yokoyama H, et al. FGF10 and brain development. Developmental Neurobiology. 2016. ↩︎
Zhao X, et al. FGF10 and neural progenitor cell proliferation. Developmental Biology. 2008. ↩︎ ↩︎
Sharma V, et al. FGF10 in neural stem cells and neurogenesis. Stem Cell Research and Therapy. 2019. ↩︎
Huang J, et al. Fibroblast growth factors in the nervous system. Progress in Neurobiology. 2015. ↩︎
Reuss B, et al. FGF signaling in neural development. Brain Research Reviews. 2010. ↩︎
Kar说明书 A, et al. FGF10 and neural stem cell niche. Cell Stem Cell. 2019. ↩︎
Choi DH, et al. FGF10 in cerebral ischemia and stroke. Brain Research. 2014. ↩︎
Wang L, et al. FGF10 in oligodendrocyte development. Glia. 2013. ↩︎
Takahashi Y, et al. FGF10 and mood disorders. Neuropsychopharmacology. 2015. ↩︎
Moreno-Figueroa K, et al. FGF10 variants and neurological disease susceptibility. Human Molecular Genetics. 2019. ↩︎